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Twenty-six cases of candidemia associated with a well-defined urinary tract source were retro-
spectively identified and reviewed. Urinary tract abnormalities were present in 23 of 26 patients
(88%), 19 (73%) of whom had urinary tract obstruction. Nineteen patients had undergone uri-
nary tract procedures before the onset of candidemia. Episodes of candidemia were brief and
low-grade in intensity (median duration, 1 day; median colony count, 1.5 cfu/10 mL of blood).
Only eight patients (31%) received >500 mg of amphotericin B. There were five in-hospital
deaths (19%); two of these deaths were attributed to candidiasis. No late complications of candi-
demia were documented for the surviving patients. Patients with urologic pathology and candi-
duria who undergo surgery or manipulation of the urinary tract are at significant risk for candide-
mia, and further studies should examine the issue of administration of prophylaxis to this group.
Candiduria often presents a dilemma to the clinician, as it
may represent colonization or infection. The prevalence of
candiduria has been estimated at 0.2%-6% [1, 2] among
asymptomatic volunteers and at 6.5%-20% among hospital-
ized patients [2, 3]. Despite the high prevalence of candi-
duria, it is not well known which patients will develop com-
plications such as candidemia. For patients in the critical
care setting, the mortality associated with urine cultures posi-
tive for Candida species was 50%, as opposed to 19% for such
patients without cultures positive for Candida [4]. On the
other hand, Schonebeck and Ansehn [5] observed 40 pa-
tients with candiduria that persisted from 1 to 12 months and
found that the infection spontaneously resolved in the major-
ity of patients, although five remained candiduric after >12
months. The goal of this retrospective study was to describe
the characteristics of candidemia arising in patients with a
well-defined urinary tract source of infection.
Materials and Methods
All patients with blood cultures positive for Candida spe-
cies at the Mayo Clinic from March 1985 to December 1987
were identified through a review of microbiological records.
Patients with candidemia were eligible for inclusion in the
study if they had concomitant candiduria and no alternative
source of candidemia. Candiduria was defined as the pres-
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ence of Candida species in urine cultures or the presence of
yeast in the urine on microscopy. Recovery of Candida spe-
cies from skin, sputum, or mucous membranes did not con-
stitute criteria for exclusion. All in-patient and out-patient
records were reviewed, and the following data were recorded:
age, sex, underlying diseases, potential risk factors, clinical
and laboratory features, radiological study findings, pathol-
ogy reports, and treatment and outcome. Blood cultures
were done for patients if they had fever or if the clinical
circumstances suggested the possibility of systemic infection.
The onset of fungemia was defined as the first day on
which blood cultures positive for Candida were obtained.
Potential risk factors were defined as: (1) administration of
antimicrobial therapy for at least 1 week before the onset of
fungemia; (2) administration of corticosteroid therapy at the
equivalent of 15 mg of prednisolone daily for at least 1 week;
(3) administration of cytotoxic therapy; and (4) manipula-
tion of the urinary tract within 2 weeks of the onset of
fungemia.
Urologic procedures include open surgery, nephrostomies,
cystoscopies, stent placements, intermittent urinary catheter-
izations, and placement of an indwelling urinary catheter.
Clinical features that were recorded included fever (tempera-
ture >38.0°C) at the onset of candidemia and evidence of
dissemination of candidal infection to other organs. Labora-
tory features reviewed included leucocyte counts and serum
creatinine levels; radiological study findings were also re-
viewed.
Microbiological studies. Quantitative blood cultures were
performed according to previously described methods [6].
Thirty milliliters of blood were drawn for each culture, and
10 mL each were inoculated into an Isolator tube (DuPont,
Wilmington, DE), a Septi-chek bottle (Roche Diagnostic
Systems, Nutley, NJ), and a nonvented bottle containing
trypticase soy broth. Aliquots from the Isolator tube wereso
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inoculated onto the surface of sheep-blood and chocolate
agar plates incubated under 5% CO2 for 7 days at 35°C. The
remainder of the sediment was inoculated onto the surface of
Sabouraud dextrose, inhibitory-mold, and brain-heart infu-
sion agar plates, which were incubated for 3 weeks at 30°C.
Plates were inspected daily. Identification of Candida species
was done using the API yeast identification system (Plain-
view, NY). Colony counts (cfus/10 mL of blood) were deter-
mined on the first day the blood cultures became positive by
counting all colonies of Candida on media plated with blood
from the Isolator tube. If more than one set of blood cultures
was positive, the colony count was divided by the number of
sets of cultures. If the Isolator tube inoculum was negative
and that in the Septi-chek bottle positive, the colony count
was recorded as zero. The duration of candidemia was de-
fined as the number of days from the first finding of a positive
blood culture up to and including the last day blood cultures
remained positive.
Results
Of the 249 patients with candidemia who were identified
during the study period, 26 (10.4%) had infection associated
with candiduria and fulfilled our criteria for inclusion in this
study (table 1). Twelve patients were male, and 14 were fe-
male. Their ages ranged from 16 years to 83 years (mean,
59.3 years; median, 67 years). Malignant disorders were pres-
ent in 19 (73%) of 26 patients; 17 of these patients had direct
primary or metastatic involvement of the urinary tract. Three
patients (12%) had received solid organ transplants, three
had nonmalignant urologic conditions (one patient each had
a stone at the ureteropelvic junction, eosinophilic cystitis,
and neurogenic bladder), and one had ulcerative colitis. Two
of 26 patients (8%) were also diabetic. Twenty-two patients
(85%) had received at least a 1-week course of antibiotics.
Seven patients (27%) had received either steroids, cytotoxic
agents, or both. None of the patients were neutropenic prior
to onset of candidemia.
Structural abnormalities of the urinary tract were present
in 23 patients (88%). Nineteen patients (73%) had evidence
of obstruction. Ileal or colonic conduits were present in six of
these 19 patients. Nineteen patients (73%) had undergone
instrumentation or open surgery involving the urinary tract
within 2 weeks before the blood cultures were found to be
positive; of these, three had had only indwelling catheters
inserted. The remaining seven patients had undergone uro-
logic procedures >2 weeks before documentation of candi-
demia.
Candiduria was documented to be present at the time of
procedures for 17 patients. For two other patients, candi-
duria had been documented to be present >1 week before
the procedure. Four patients were noted to have candiduria
after a procedure; subsequently, cultures of blood from these
patients were positive for Candida species. The interval be-
tween the most-recent procedure and onset of candidemia
ranged from <1 day to 10 days (mean, 3.8 days; median, 3
days); three patients became febrile and candidemic within
24 hours after a procedure was performed.
Fever was documented in 24 patients (92%). Blood cul-
tures were done for the remaining two patients because radio-
logical findings suggested abscess formation in one, and per-
sistently positive urine cultures, pyuria, leukocytosis, and
flank pain were documented for the other. Nine (38%) of 24
patients had leukocytosis, with leukocyte counts of
>12,000/mm 3 . The serum creatinine level was increased
(> 1.2 mg/dL) in 14 patients at the time of admission to the
hospital and in 21 patients at the time of candidemia. No
abnormalities suggestive of disseminated candidiasis were
found on ophthalmologic examination of 16 patients or in
four patients who underwent transthoracic echocardiog-
raphy.
Microbiological results. Blood cultures yielded Candida
albicans for 19 patients (73%); Torulopsis glabrata for five
patients (19%); and Candida tropicalis, Candida parapsilosis,
and an unidentified Candida species for three patients (8%).
For one patient, blood culture yielded both C. albicans and
T. glabrata. For 21 patients, the fungus in urine was identi-
fied to the species level, and the isolates all corresponded to
the blood isolates, including those from the patient with poly-
microbial candidemia.
The colony count, as assessed using the Isolator tube,
ranged from 1 cfu to 54.5 cfu/10 mL of blood, with a median
count of 1.5 cfu/10 mL of blood. For two patients, cultures
performed with use of the Isolator tube were negative; only
those performed with the Roche bottle were positive.
Twenty-one patients (85%) had counts less than or equal to 5
cfu/10 mL of blood.
The number of sets of blood cultures done ranged from 2
to 24 (median, 12 sets; mean, 12.6 sets). The number of days
over which cultures were done ranged from 1 to 13 days
(median, 6 days; mean, 6.2 days). Twenty-one patients had
follow-up blood cultures that were documented to be nega-
tive. One patient had positive blood cultures on 3 consecu-
tive days and died on the fourth day, probably still candide-
mic. The remaining four patients were febrile at the onset of
candidemia; however, their symptoms resolved, and re-
peated cultures were not performed.
The duration of candidemia ranged from 1 to 12 days,
with 15 patients having candidemia for 1 day. The median
duration of candidemia for all patients was 1 day. The pa-
tient with the longest duration of candidemia (case 10) had
an obstruction of the urinary tract that required repeated
procedures, and his urine cultures remained positive.
Radiological findings. Findings on radiological studies of
the urinary tract done immediately before and after episodes
of candidemia were reviewed. These studies included ultraso-
nography, computerized tomography, and antegrade or intra-
venous pyelography. Nineteen patients had evidence of hy-
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Table 1. Summary of clinical features, microbiological aspects, treatment, and outcome for 26 patients with candidemia and candiduria.
1 61/M CA, colon Bilateral
2 78/M Benign
prostatic
hypertrophy,
ureteric
stone
Unilateral
3 83/F CA, bladder Bilateral
4 70/M CA, bladder Unilateral
5 67/F CA, bladder Bilateral
6 67/F CA, rectum Bilateral
7 68/M CA, tongue None
8 67/M CA, kidney None
9 53/M CA, pancreas Unilateral
10 68/M CA, bladder Unilateral
1 1 36/F Eosinophilic
cystitis
None
12 70/F CA, breast Bilateral
13 66/M CA, pancreas None
14 34/F CA, ovary Unilateral
15 64/F CA, breast Unilateral
16 26/F Renal
transplant
None
17 16/F Neurogenic
bladder
Bilateral
18 28/M Ulcerative
colitis
None
19 63/F CA, bladder Bilateral
20 79/M CA, bladder Unilateral
21 68/M CA, rectum Bilateral
22 78/F Lymphoma Bilateral
23 25/M Liver
transplant
Unilateral
24 68/F Lymphoma Bilateral
25 79/M CA, prostate Unilateral
26 33/F Renal
transplant
None
Nephrostomy
. . . t
Candidemia
Renal
involvement
Amphotericin B
(total dose)
Outcome (duration of
follow-up or cause of
death)
Duration
(d)
Counts
(cfu/10 mL)
1 1 Proven 1.0 g Died (4 mo)
6 3 ND 0.5 g Alive (22 mo)
1 1 ND None Died (21 mo)
1 7 Proven 0.05 g Alive (1 mo)
5 5 Possible 1.5 g Alive (1 mo)
1* 2 ND None Died (14 mo)
1 2 Possible 1.0 g Died (2 mo)
3* 54.5 Proven 0.02 g Died in hospital
(candidiasis was
contributing factor)
8 11 ND 0.5 g Died (6 mo)
12 1 Possible 0.25 g Alive (11 mo)
7 16 ND 0.4 g Alive (10 mo)
6 1 Proven 0.35 g Died (9 mo)
1 18.5 ND None Alive (1 mo)
1 1 ND 0.5 g Died (2 mo)
1 0 ND None Died in hospital
(pulmonary embolism)
5 3 Proven 0.5 g Transplant nephrectomy;
alive (1 y)
1 5 ND None Alive (43 mo)
1 1 ND None Alive (1 mo)
2 2 ND 0.2 g Alive (36 mo)
1 2 Possible None Alive (4 y)
1 1 ND None Candidemia recurred;
died (3 y)
1 0 Possible 0.05 g Died in hospital
(lymphoma)
1 1 Proven 0.08 g Died in hospital
(candidiasis and liver
failure at autopsy)
5 1 ND 1.0 g Died in hospital
(lymphoma)
2* 1 Possible 0.5 g Alive (46 mo)
1 1 ND 0.2 g Alive (52 mo)
Nephrostomles
Stents
Cystoscopy,
cystectomy
UC alone
UC alone
. . . t
Stents
Nephrostomy, stents,
cystoprostatectomy
Intermittent
catheterization
. . . t
UC alone
Stents
Nephrostomy, stents
Antegrade
pyelogram,
cystoscopy
Nephrostogram,
colonic conduit
. . . t
Stents, cystectomy
Stents, cystectomy
Nephrostomy
Stent, nephrostomies,
cystoscopy
Stent, cystoscopy,
ureteric
anastomosis
. . . t
Case
	 Underlying 	 Urinary tract
	
Urologic
no.	 Age/sex 	 condition
	 obstruction 	 procedure
NOTE. CA = cancer; proven = renal involvement documented on microbiology or histology; ND = not documented; possible = renal involvement
suggested by radiological study results; UC = urinary catheterization.
* Cultures not repeated.
t Procedures were performed >2 weeks before onset of candidemia.
dronephrosis; two patients had debris in their collecting sys-
tems of indeterminate etiology. One patient had findings
strongly suggestive of an abscess in the lower pole of the
kidney, while three had abnormal collections of fluid in the
perinephric space. Changes suggestive of renal parenchymal
disease were observed for four other patients. Precise delin-
eation of parenchymal involvement was hampered by the
inability to administer contrast agents to many patients with
poor renal function.
Percutaneous aspiration of renal tissue or perinephric fluid
was done for five patients, and Candida species were cul-
tured from all of the specimens. For three patients the inves-
tigations were done while they had candidemia; for the other
two patients, aspiration was done 3 days after candidemia
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resolved in case 1 and 2 months before it developed in case
8. Carcinoma of the kidney recurred in case 8 and was com-
plicated by the formation of an abscess, which was subse-
quently drained surgically. For one additional patient (case
23), Candida grew from renal tissue obtained at autopsy, 9
days after an episode of candidemia that lasted 1 day; urine
cultures had previously been positive for Candida species on
9 different days before the development of candidemia.
Treatment and outcome. Eighteen patients (69%) re-
ceived amphotericin B for treatment of candidemia. Eight
(31%) of 26 patients received >500 mg of amphotericin B;
one patient in this group died of the primary disease (lym-
phoma). The remaining seven patients were observed for pe-
riods ranging from 1 to 22 months after the onset of candide-
mia (mean, 8 months; median, 2 months). Among the 10
patients who received amphotericin B in total doses of <500
mg, there were three deaths before completion of amphoteri-
cin therapy. Candidiasis was thought to be a contributing
cause of death for one patient because he remained candide-
mic until his death, while disseminated candidiasis was docu-
mented at autopsy in another. The remaining seven patients
received a median total dose of 200 mg of amphotericin B;
this group included one patient who received 56 mg of am-
photericin B followed by a 2-month course of oral ketocona-
zole (400 mg daily). These patients did not receive addi-
tional antifungal therapy and were followed for periods
ranging from 1 to 52 months (mean, 23 months; median, 11
months); no evidence of candidiasis was observed.
Among the remaining eight patients who received no anti-
fungal therapy for candidemia, there was one death due to
recurrent pulmonary embolism. The remaining seven pa-
tients were followed for periods ranging from 1 to 57 months
(mean, 23 months; median, 14 months). One patient (case
21) continued to have candiduria and urinary tract obstruc-
tion requiring repeated procedures and had reinfection of his
bloodstream with the same species of Candida 8 months after
the first episode.
Overall, there were five in-hospital deaths, giving a mortal-
ity of 19% in this patient population. Two deaths (8%) were
directly attributed to candidiasis.
Discussion
The prevalence of candiduria among hospitalized patients
has been estimated to range from 6.5% [3] to 20% [2]. Despite
this prevalence candidemia from a urinary tract source seems
to be a relatively rare complication, since a prospective study
of 28 patients with candiduria identified only one patient
(3.6%) who developed candidemia [7]. In our study of 249
consecutive cases of candidemia, a definite urinary source
was identified in 26 patients (10.4%); this figure is in agree-
ment with those of Dyess et al. [8], who identified the urinary
tract as the probable source of candidemia in nine of 83
patients (10.8%). Our estimate is probably conservative, as
those cases with other potential sources of infection were
excluded.
Patients with candidemia from a urinary source had a
characteristic profile: most had significant anatomical uri-
nary-tract pathology that was frequently complicated by ob-
struction, and these patients were subject to urological pro-
cedures such as stenting, insertion of nephrostomy tubes, or
major urinary tract surgery.
In contrast to candidemia that arises from an intravascular
focus [9], episodes of candiduria-associated candidemia were
low-grade and of a short duration, and in many cases re-
solved spontaneously prior to the institution of specific anti-
fungal therapy. Three patients became candidemic within 24
hours after a procedure; however, candidemia in most pa-
tients did not occur immediately after manipulation, but sev-
eral days later. A plausible explanation for this course of
events includes the following factors: (1) an ascending infec-
tion facilitated by urinary manipulation in the presence of
candiduria; (2) subsequent development of micro- or macro-
foci of renal parenchymal infection; and (3) limited or tran-
sient low-grade candidemia, perhaps precipitated by addi-
tional insults. Alternatively, in some instances candidemia
may have occurred spontaneously and coincidentally with
urinary tract manipulation.
Only eight patients received a cumulative dose of >500
mg of amphotericin B. One patient in this group died while
receiving therapy, presumably of lymphoma, as there was no
evidence of residual infection with Candida. Among the 18
patients who received no antifungal therapy or received a
cumulative dose of <500 mg of amphotericin B, there were
four in-hospital deaths. Disseminated candidiasis was docu-
mented at autopsy in one patient, and candidiasis was
thought to be a contributing cause of death for another pa-
tient.
The mortality rate in this series is lower than that reported
in studies of other patient populations with candidemia (e.g.,
38% among surgical patients [10] and 70% among immuno-
suppressed patients [11]). Lower mortality may be related to
the transient duration of candidemia and the low colony
counts. The duration of candidemia has been identified as a
risk factor for tissue invasion in marrow transplant recipients
[12]. Although quantitative colony counts have been found
to correlate with the clinical course of bacteremic patients
[13], a similar association was not observed for candidemia
in one study [14].
Optimal antifungal therapy for candidemia has not been
established. Initial treatment with amphotericin B is usually
advised [15], but optimal duration of therapy is controversial
[16], particularly when infection is not associated with a re-
movable source such as an intravenous catheter. Solomkin et
al. [17] suggest that a total dose of 6 mg-8 mg/kg may be
sufficient to clear fungemia in postsurgical patients [17]. Ex-
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perience with the new imidazole drugs for treatment of sys-
temic candidiasis and candidemia is limited [18, 19].
Our retrospective experience does not provide a basis for
making specific treatment recommendations. However, the
documentation of an association between renal parenchymal
infection and Candida-related mortality suggests the need for
specific treatment with antifungal agents despite the appar-
ent transient nature of the episodes of candidemia.
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